📚 Article Archive

Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration.

Taiyo Shijo, Yoichi Sakurada, Seigo Yoneyama +6 more · 2020 · Pharmaceuticals (Basel, Switzerland) · MDPI · added 2026-04-24

Taiyo Shijo, Yoichi Sakurada, Seigo Yoneyama, Wataru Kikushima, Atsushi Sugiyama, Mio Matsubara, Yoshiko Fukuda, Fumihiko Mabuchi, Kenji Kashiwagi Show less

We investigated whether polygenic risk score (PRS) was associated with one-year outcome of as-needed aflibercept therapy for exudative age-related macular degeneration (AMD), including AMD (

📄 PDF DOI: 10.3390/ph13090257

CETP

👤 Taiyo Shijo

Genetic Factors Associated with Intraocular Inflammation After Brolucizumab Administration in Patients with Exudative Age-Related Macular Degeneration.

Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration.